Background: Complex wounds present a substantial economic burden on healthcare systems, costing billions of dollars annually in North America alone. The prevalence of complex wounds is a significant patient and societal healthcare concern and cost-effective wound care management remains unclear. This article summarizes the cost-effectiveness of interventions for complex wound care through a systematic review of the evidence base.
Background
Complex wounds are those that do not heal after a period of 3 months or more [1] . These types of wounds are a significant burden on the healthcare system and result in patient and caregiver stress, economic loss, and decreased quality of life. At least 1% of individuals living in high economy countries will experience a complex wound in their lifetime [2] , and over 6.5 million individuals have a complex wound in the United States alone [3] . Moreover, these types of wounds have a significant economic impact. For example, $10 billion United States dollars (USD) per year in North America is spent managing complex wounds [4] , and 4% of the annual National Health Service expenditure in the United Kingdom is spent on care for patients with pressure ulcers [5] .
There are three main categories of complex wounds: i) wounds resulting from chronic disease (e.g., venous insufficiency, diabetes), ii) pressure ulcers, and iii) nonhealing surgical wounds [6] [7] [8] . Treatment is targeted to the type of wound. Managing complex wounds resulting from disease usually involves improving the underlying disease; for example, optimizing diabetes control for patients with diabetes [9] . A clinical assessment and history of mobility and neurological disability is often necessary to treat patients with pressure ulcers [9] . Considerations for managing surgical wound infections include previous antibiotic treatment and immune response [3] .
It is estimated that the global wound care market will reach over $22 billion USD annually by 2020 [10] . Due to the burgeoning costs from the management of patients requiring complex wound care, policymakers are interested in finding cost-effective treatments. However, the cost-effectiveness of all interventions available to treat complex wounds is currently unclear. As such, we sought to elucidate cost-effective treatment strategies for complex wounds through a systematic review of costeffectiveness analyses.
Methods

Protocol
The systematic review question was posed by members of the Toronto Central Local Health Integrated Network. In collaboration with the Toronto Central Local Health Integrated Network, our research team prepared a draft protocol that was revised to incorporate feedback from systematic review methodologists, policymakers, and clinicians with expertise in wound care (Additional file 1). Our protocol also included conducting a related project comprising an overview of systematic reviews for treating complex wounds, and these results are available in a separate publication [11] .
Information sources and search strategy
On October 26, 2012, an experienced librarian conducted comprehensive literature searches in the following electronic databases from inception onwards: MEDLINE, EMBASE, and the Cochrane Library. The 
Eligibility criteria
Inclusion criteria were defined using the 'Patients, interventions, comparators, outcomes, study designs, timeframe' (PICOST) framework [13] , as follows:
Patients
Adults aged 18 years and older experiencing complex wounds. Complex wounds included those due to chronic disease (such as diabetic foot ulcers or venous leg ulcers), pressure ulcers (such as decubitus ulcers or bed sores), and non-healing surgical wounds.
Interventions
All complex wound care interventions were included, as identified from our overview of systematic reviews [11] and outlined in Additional file 3.
Comparators
All comparators were eligible for inclusion, including any of the eligible interventions in comparison with each other or versus no treatment or placebo or usual care.
Outcomes
Cost-effectiveness (i.e., both incremental cost and incremental effectiveness) was included, where effectiveness was measured by at least one of the following outcomes: quality-adjusted life-years (QALYs), wounds healed, ulcer-free/healing time, wound size reduction/improvement, or hospitalizations (number/length of stay).
Study designs
Economic evaluations were included in which the incremental cost-effectiveness ratios (ICERs) were reported or could be derived.
Timeframe
We did not limit inclusion to year of publication.
Other limitations
We limited cost-effectiveness analyses to those based on a study with a control group, and where the data were from direct comparisons (versus a review using indirect data). Both published and unpublished studies were eligible for inclusion. Although we focused inclusion on those studies written in English, we contacted the authors of potentially relevant non-English studies to obtain the English translation.
Screening process for study selection
The team pilot-tested the pre-defined eligibility criteria using a random sample of 50 included titles and abstracts. After 90% agreement was reached, each title and abstract was screened by two team members, independently, using our Synthesi.SR tool [14] . Discrepancies were resolved by discussion or the involvement of a third reviewer. The same process was followed for screening full-text articles that were identified as being potentially relevant after screening their titles and abstracts.
Data abstraction and data collection process
The team pilot-tested data abstraction forms using a random sample of five included cost-effectiveness analyses. Subsequently, two investigators independently read each article and abstracted relevant data. Differences in abstraction were resolved by discussion or the involvement of a third reviewer. Data items included study characteristics (e.g., type of economic evaluation, time horizon, treatment interventions examined, study comparators), patient characteristics (e.g., clinical population, wound type), and cost-effectiveness results (e.g., ICERs, cost per QALY, cost per wound healed). The perspective of the economic evaluation was categorized as: patient, public payer, provider, healthcare system, or society [15] . Cost-effectiveness studies can have four possible overall results, which are often represented graphically in quadrants on a cost-effectiveness plane [16] . The possibilities for the intervention versus a comparator are: 1) more effective and less costly, which we noted as 'dominant'; 2) more effective and more costly; 3) less effective and less costly; and 4) less effective and more costly, which we noted as 'dominated'. The first possibility is considered to be cost-effective; whereas possibility 4 is not cost-effective. Situations 2 and 3 requires judgment by the decision-maker to interpret [17] , and in such cases, the decision is often dependent on the decision-maker's willingness to pay. For interventions that were found to be more effective yet more costly (i.e., situation 2) or less effective and less costly (situation 3), ICERs were reported or derived from both the differences in cost (i.e., incremental cost) and effectiveness (i.e., incremental effectiveness) between the study's intervention and comparator groups using the formula: (Cost of the intervention -Cost of the comparator) ÷ (Effectiveness of the intervention -Effectiveness of the comparator)
To assess key variables influencing the costeffectiveness results, sensitivity analyses, level of uncertainty in the cost and benefit estimates, and incremental variabilities (i.e., the variability of the incremental cost and the variability of the incremental effectiveness), were reported.
Authors of the included cost-effectiveness analyses were contacted for data verification, as necessary. Further, multiple studies reporting the same economic data were sorted into the major publication (e.g., most recent paper or largest sample size) and companion report. Our results focus on the major publications and the companion reports were used to provide supplementary material.
Methodological quality appraisal
The methodological quality of the cost-effectiveness analyses was appraised using a 10-item tool developed by Drummond et al. (Additional file 4) [18] . The items on this tool include the appraisal of question definition, description of competing alternatives, effectiveness of the intervention, consideration of all relevant costs, measurement of costs, valuation of costs and consequences, cost adjustment/discounting, incremental analysis, uncertainty/sensitivity analysis, and discussion of study results. The Drummond score can range from 0 to 10. Each included cost-effectiveness analysis was appraised by two team members and conflicts were resolved by discussion or the involvement of a third reviewer.
Synthesis
Since the purpose of this systematic review was to summarize the cost-effectiveness of interventions for complex wound care, the results are reported descriptively. The costing data from all studies were converted to 2013 USD to increase the comparability of the economic results across cost-effectiveness studies. This process entailed first converting the currencies into USD using purchasing power parities for the particular year of the data [19, 20] , and then adjusting these for inflation to the year 2013 (rounded to the nearest dollar) using the consumer price index for medical care in the United States [21] .
Results
Literature search and screening
The literature search identified 422 potentially relevant full-text articles after screening 6,200 titles and abstracts ( Figure 1 ). There were 59 included cost-effectiveness analyses that fulfilled our eligibility criteria and were included , plus an additional three companion reports [81] [82] [83] .
Study and patient characteristics
The cost-effectiveness analyses evaluated interventions to treat venous ulcers (41%), diabetic ulcers (27%), and pressure ulcers (24%) ( Table 1 ). The studies were published between 1988 and 2012. Most of the papers were conducted in the United Kingdom (29%) and United States (27%). Almost half (49%) reported private or mixed (private and public) funding sources of the studies, while one-third (34%) did not report a source of funding. While the majority of studies based effectiveness on a (single) randomized clinical trial (75%), only a few based effectiveness on a systematic review (9%) and 15% were based on observational studies (Tables 2, 3, 4, 5 and 6). Almost half (46%) of the economic studies included a sample size of 10 to 100 patients and the rest had a sample of >100 patients. In addition, 48% were conducted in a timeframe of 12 weeks or less, while the other studies had a duration of >12 weeks follow-up. Across the 59 economic studies, 9 different units of effectiveness were used, with the most common ones being healed wound (44%) and QALY (17%). Regarding the perspective of the cost-effectiveness analysis, almost half (46%) did not report this explicitly and 29% reported using the public payer perspective.
Methodological quality appraisal
Approximately 71% (42 out of 59) of the costeffectiveness analyses had a score of 8 or higher out of a total possible score of 10 (Additional file 5, Figure 2 ). Using the Drummond 10-item tool [18] , the key methodological shortcoming across the cost-effectiveness analyses was that only 51% (30 out of 59) had established the 'effectiveness' of the intervention using data from efficacy studies (i.e., systematic reviews, randomized clinical trials or observational studies) that had sufficiently large sample sizes according to the International Conference on Harmonisation guidelines for establishing efficacy [84] . Consistent methodological strengths across the costeffectiveness analyses included a clear research question, costs and consequences measured in appropriate physical units, credibly valued costs and consequences, and discounted costs (when applicable).
Cost-effectiveness results
Due to the large number of cost-effectiveness studies included and the numerous results, we have focused on dominant results in the text. However, all of the costeffectiveness results are presented in Tables 7, 8, 9, 10 and 11 and the sensitivity analyses, level of uncertainty, and incremental variabilities are outlined in Additional file 6.
Venous ulcers
Twenty-four cost-effectiveness analyses examined interventions for venous ulcers ( effective and less costly) [22] [23] [24] [26] [27] [28] [29] 31, 32, 35, 38, [42] [43] [44] [45] , and 12 of these were studies with a Drummond score ≥8 [24, [26] [27] [28] [29] 32, 35, 38, 39, 42, 44, 45] . These included Apligraf (Graftskin) vs. Unna's Boot [42] , Unna's boot vs. hydrocolloid (DuoDERM) [32] , micronized purified flavonoid fraction plus usual care vs. usual care alone [24] , durable barrier cream vs. no skin protectant [26] , pentoxifylline plus compression vs. placebo plus compression [27] , Manuka honey dressing vs. usual care [29] , amelogenin plus compression therapy vs. compression therapy only [45] , and four-layer compression bandaging vs. usual care [35, 38, 44] . Although four-layer compression bandaging vs. short-stretch compression bandaging was found to be dominant in two studies [28, 39] ], this intervention was more effective and more costly in another economic evaluation [41] . Dominant interventions from four studies scoring <8 on the Drummond tool [22, 23, 31, 43] included hydrocolloid dressing vs. Vaseline gauze dressing [22] , hydrocolloid dressing plus compression hosiery vs. Unna's boot [31] , Thera-boot vs. Unna's boot [23] , and community leg ulcer clinic vs. usual care clinic [43] .
Mixed venous and venous/arterial ulcers
Two cost-effectiveness analyses evaluated interventions for mixed venous and venous/arterial ulcers (Table 8 ) [46, 47] . Only one study found an intervention to be dominant (and had a Drummond score ≥8); hydrocolloid (DuoDERM) dressing was dominant compared to saline gauze [47] .
Diabetic ulcers
Sixteen cost-effectiveness analyses examined interventions for diabetic ulcers (Table 9 ) [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] . Twelve studies found the interventions were dominant [48] [49] [50] [52] [53] [54] 56, 57, 59, [61] [62] [63] , and 10 of these were studies with a Drummond score ≥8 [49, 50, [52] [53] [54] 56, 57, 59, 61, 62] . These included becaplermin gel (containing recombinant human platelet-derived growth factor) plus good wound care (GWC) vs. GWC alone (note: the various GWC definitions used are outlined in Table 9 ) [57, 62] , cadexomer iodine ointment vs. usual care [49] , filgrastim vs. placebo [50] , intensified treatment vs. usual care [52] , staged management diabetes foot program vs. usual care [53] , ertapenem vs. piperacillin/tazobactam [54] , ampicillin/sulbactam vs. imipenem/cilastatin [56] , Apligraf (skin substitute) plus GWC vs. GWC alone [59] , and promogran dressing plus GWC vs. GWC alone [61] . Hyperbaric oxygen therapy plus usual care vs. usual care alone was found to be dominant in one study [63] , yet was more effective and more costly in another economic evaluation [51] .
Dominant interventions from studies scoring <8 on the Drummond tool included hyperbaric oxygen therapy vs. control [48] , and hyperbaric oxygen therapy plus standard care vs. standard care alone [63] .
Pressure ulcers
Fourteen cost-effectiveness analyses evaluated pressure ulcer interventions (Table 10 ) [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] . Ten studies found the interventions were dominant [64, 67, 69, [71] [72] [73] [74] [75] [76] [77] , and four of these were studies with a Drummond score ≥8 [69, 71, 76, 77] . These included moisture vapor permeable dressing vs. gauze [for grade II pressure ulcers] [77] , advanced dressings vs. simple dressings [69] , and hydrocolloid (DuoDERM) vs. gauze [76] . Collagenase-containing ointment (Novuxol) vs. hydrocolloid (DuoDERM) dressing Table 7 Cost-effectiveness analysis (CEA) outcomes for venous ulcers (n = 24) (Continued) Guest 2009 Guest (2007 [45] Amelogenin plus compression therapy vs. compression therapy only c ICER was mostly due to an extra 3 patients hospitalized in control group… "probably due to random variation". If remove these costs, the dominance is reversed in favor of UC. d Unable to calculate specific ICER for these 2 studies because the data was not reported for all treatment arms or presented in a figure only but the overall result (more costly & more effective) was reported. was found to be dominant in one study [71] , while collagen (Medifil) vs. hydrocolloid (DuoDERM) was more effective and more costly in another cost-effectiveness analysis [70] .
The following interventions were dominant in six studies with a Drummond score <8: constant force technology mattress vs. low-air-loss mattress [64] , silver mesh dressing vs. silver sulfadiazine cream [67] , balsam Peru plus hydrogenated castor oil plus trypsin ointment vs. balsam Peru plus hydrogenated castor oil plus trypsin ointment plus other treatment (unspecified) for stage 1 and 2 wounds [72] , balsam Peru plus hydrogenated castor oil plus trypsin ointment plus other treatment (unspecified) vs. other treatment (unspecified) for stage 1 wounds [72] , balsam Peru plus hydrogenated castor oil plus trypsin ointment vs. other treatment (unspecified) for stage 2 wounds [72] , polyurethane foam dressing vs. saline gauze [73] , sequential granulocytemacrophage/colony-stimulating factor and basic fibroblast growth factor vs. basic fibroblast growth factor alone [74] , sequential granulocyte-macrophage/colonystimulating factor and basic fibroblast growth factor vs. granulocyte-macrophage/colony-stimulating factor alone [74] , and new hospital incentive system vs. nonintroduced control [75] .
Mixed wound types
Three cost-effectiveness analyses evaluated mixed complex wound types (Table 11 ) [78] [79] [80] . One study with a Drummond score ≥8 found that a multidisciplinary wound care team was dominant compared to usual care [80] .
Discussion
We conducted a comprehensive systematic review to summarize the cost-effectiveness of interventions for complex wound care including data from 59 costeffectiveness analyses. These economic studies examined numerous interventions and comparators and used different outcomes to assess effectiveness. In a few situations, the intervention considered in one costeffectiveness analysis comprised the comparator in another cost-effectiveness analysis. Therefore, costeffectiveness results are presented as comparisons of one treatment option relative to another. Based on evidence from 42 cost-effectiveness studies with a Drummond score ≥8, 22 intervention comparisons were dominant (Additional file 7 Our results highlight a need for a future network meta-analysis given the numerous interventions and comparators available. Network meta-analysis is a statistical technique that can be used to combine direct evidence of effectiveness from head-to-head studies and indirect evidence of the relative benefits of interventions versus a common comparator (usually placebo). This powerful statistical approach can also be used to select the best treatment option available from a ranking of all treatments. An attractive property of network metaanalysis is that it allows researchers and health economists the opportunity to use the ranking analysis to generate a de novo cost-effectiveness analysis more efficiently. Another potential future study is to conduct a systematic review of clinical practice guidelines on complex wounds, and compare the interventions recommended in these with those found to be cost-effective in our review.
The major methodological quality limitation found in the included cost-effectiveness analyses was that the majority did not adequately establish the effectiveness of the wound care intervention using data from systematic reviews, randomized clinical trials, or observational studies that had sufficiently large sample sizes. Moreover, many of the included economic studies did not report on uncertainty of the cost-effectiveness estimates, incremental variabilities, or sensitivity analyses, thereby further limiting the utility of those results. Further, many of the cost-effectiveness analyses did not assess long-term cost-effectiveness, and the choice of timeframe for an economic evaluation might significantly affect the costeffectiveness results. Given the chronic nature of many types of wounds, economic modeling of a longer time horizon would provide a clearer picture in many circumstances. As an example, an intervention might be more effective yet more costly in the first 2 months of usage but it might be cost saving over a 1 year or longer timeframe due to overall fewer additional interventions required. Furthermore, most of the cost-effectiveness studies did not include information on patient-reported quality of life, which is a major limitation of this literature. The majority of the included economic studies were from European countries and 16 were from the United States. When trying to apply the cost-effectiveness results to a country-specific context, several factors need to be assessed such as the perspective of the economic evaluation (e.g., public payer, healthcare provider), the type of healthcare system (e.g., publicly-funded healthcare), the local practice of medicine, and local costs.
There are a few limitations related to our systematic review process worth noting. Due to resource constraints, we only included studies written in English. However, we contacted authors of non-English studies to obtain the English translations. In addition, although we contacted authors to share their unpublished data, only published literature was identified for inclusion. Finally, due to the numerous number of cost-effectiveness analyses included, we focused reporting on those with dominant results and a score ≥8 on the Drummond tool in the main text. We note that this is an arbitrary cut-off, and there is not an agreed upon method to provide a summary score on this tool. However, all of our results for all studies are presented in the tables and appendices despite dominance and score on the Drummond tool.
Conclusions
We conducted a comprehensive systematic review of cost-effectiveness studies for interventions to treat adult patients with complex wounds. Our results can be used by decision-makers to assist in maximizing the deployment of clinically effective and resource efficient wound care interventions. Our analysis also highlights specific treatments that are not cost-effective, thus indicating areas for potential improvements in efficiency. A network meta-analysis and de novo cost-effectiveness analysis will likely bring additional clarity to the field, as some of the findings were conflicting.
